ER
MDGL icon

Enlightenment Research’s Madrigal Pharmaceuticals MDGL Stock Holding History

Enlightenment Research’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$23K – 427
2018
Q4 		$23K Buy
+200
New +$31K 0.03% 427

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Enlightenment Research's MDGL Position: Q1 2019 in Review

Enlightenment Research sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2019, closing a stake of 200 shares — an estimated $23K sold.

Enlightenment Research first reported a position in MDGL in Q4 2018 and held it in 1 quarter. The position peaked at $23K in Q4 2018. 135 funds tracked by Wall St. Rank hold MDGL as of Q1 2019.

  • Enlightenment Research reported no remaining Madrigal Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 200 Madrigal Pharmaceuticals shares in Q1 2019, an estimated $23K.
  • Enlightenment Research first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Madrigal Pharmaceuticals position peaked at $23K in Q4 2018.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.